The efficacy of intradermal hyaluronic acid filler as a skin quality booster: A prospective, single-center, single-arm pilot study.
Joo Hee Lee, Jemin Kim, Yun Na Lee...
https://pubmed.ncbi.nlm.nih.gov/37705328/Actively Recruiting
Led by Promoitalia Group Spa · Updated on 2026-10-14
43
Participants Needed
1
Research Sites
25 weeks
Total Duration
Researchers are evaluating the performance and safety of the MD60000 medical device, a sterile, biodegradable intradermal gel containing 3.3% linear hyaluronic acid combined with polylactic acid PLA, designed to correct facial skin imperfections caused by aging such as wrinkles. This single-center, uncontrolled, single-arm clinical study aims to gather clinical data to support regulatory conformity under European Medical Device Regulation 2017745. Forty-three adult participants aged 18 to 65 with facial skin defects scoring at least 1 on the Lemperle Wrinkle Severity Scale are enrolled. Participants receive two intradermal injections of MD60000 gel, up to 2 milliliters per session, administered at baseline and approximately 21 days later. The study includes four main visits screening and baseline assessments with photographic documentation and wrinkle evaluation, two treatment sessions, and a follow-up visit 30 days after the second treatment where final assessments and patient satisfaction surveys are completed. The study lasts between 45 and 65 days per participant. Throughout the trial, researchers monitor wrinkle improvement using the Lemperle Wrinkle Severity Scale and patient satisfaction through the Global Aesthetic Improvement Scale GAIS. Safety is carefully assessed by tracking adverse events and device-related effects from the start of treatment through the follow-up. Statistical analysis evaluates both safety and performance outcomes. The total duration for the entire clinical investigation is about six months.
CONDITIONS
Evaluation of the Performance and Safety of the MD60000 Device in the Treatment of Skin Imperfections Due to Aging.
G
Grazia Iannacci
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Promoitalia Group Spa
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 2 weeks
Participants are screened for eligibility to participate in the trial, including medical history, consent, and baseline wrinkle assessments with photographs.
1 visit (screening and baseline)
Duration - Approximately 3 weeks between injections
Participants receive two intradermal injections of the MD60000 gel on Day 0 and around Day 21, with up to 2 milliliters per session to treat facial wrinkles.
2 treatment visits
Duration - 30 days after final treatment
Participants return for a follow-up visit 30 days after the second treatment to assess wrinkle improvement, take final photographs, and collect patient satisfaction and safety data.
1 follow-up visit
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Joo Hee Lee, Jemin Kim, Yun Na Lee...
https://pubmed.ncbi.nlm.nih.gov/37705328/Promoitalia Group Spa
Lead Sponsor